NIH has sent a letter, dated Dec 1, to Robert Sachs and Clare Love, regarding the longstanding petition to HHS to use the federal government’s rights in the patented inventions for enzalutamide, marketed by Astellas in the USA at prices 3 to 7 times higher than in all other high income countries. According to the NIH: “We are currently coordinating with HHS to review and assess.”
NIH-Response2Sachs-Love1dec2022
We are currently coordinating with HHS to review and assess the information submitted in the 2021 petition requesting the government to use its march-in authority for Xtandi (enzalutamide) to determine whether the initiation of the march-in orocedures outlined in 37 CFR §401.6 may be warranted.
It’s been over a year.
The NIH was responding to this letter from Sachs and Love.
https://www.keionline.org/38128
Probably motivated also by this letter from 19 NGOs, https://www.keionline.org/38148
And a letter from PIRG.
